Dana Cipriano

Dana Cipriano's Title

Dana Cipriano holds the title of Senior Vice President (SVP) of Testing Analytical Services, & Plasmids. In this role, Dana is responsible for overseeing testing operations and ensuring the quality and safety of cell and gene therapy products. This high-level position signifies Dana's extensive expertise and leadership in the biotechnology sector, particularly in the areas of laboratory operations, project management, and strategic business development.

Dana Cipriano's Education and Expertise

Dana Cipriano has a robust educational background, holding a Master's degree in Microbiology from Thomas Jefferson University and a Bachelor's degree in Biology from Rutgers University. Dana has also completed an Executive Education Certification from The Wharton School, which complements a Project Management Professional (PMP) certification. This educational foundation provides Dana with a deep understanding of both the scientific and business aspects of biotechnology, enabling Dana to design effective testing programs and strategic initiatives.

Dana Cipriano's Background

With over 20 years of experience in biotechnology and cell and gene therapy, Dana Cipriano has held various leadership roles in Laboratory Operations and Project Management. Dana's career has been marked by a focus on designing processes and testing programs that drive sustainable growth and profitability. Dana's comprehensive understanding of the field has enabled the development of robust strategies for testing and quality assurance in clinical and commercial products.

Dana Cipriano's Achievements

Dana Cipriano’s career is decorated with significant achievements, particularly during Dana’s tenure as Senior Director of Testing Operations and Strategic Projects for WuXi Advanced Therapies. Dana played a crucial role in directing testing operations for cell and gene therapy and biologics testing, including characterization, release, safety, and viral clearance testing. Dana also helped formulate the overall testing business strategy and drove tactical implementation plans to achieve strategic objectives. Notably, Dana developed an integrated program for a new corporate strategy focused on scalability in cell and gene therapy testing services and designed a state-of-the-art cGMP testing facility.